Sign In
Buy ESPR
$3.14
+0 (+0%)
At Close: Jun 03, 2026
Esperion's stock tumbles after disclosing dispute about milestone payment
08:21am, Thursday, 16'th Mar 2023
Shares of Esperion Therapeutics Inc. ESPR plunged about 56% in premarket trading on Thursday, the day after the company told investors that there is a dispute about a million milestone payment for its
Esperion Therapeutics (ESPR) Down 24% in a Week: Here's Why
12:15pm, Friday, 10'th Mar 2023
Shares of Esperion Therapeutics (ESPR) fell last week as the company's cardiovascular outcome CLEAR study results failed to meet investor expectations.
2 Biotech Stocks Options Traders Are Watching
01:36pm, Monday, 06'th Mar 2023
At least two biotech stocks are seeing increased scrutiny in the options pits, with BridgeBio Pharma Inc (NASDAQ:BBIO) and Esperion Therapeutics Inc (NASDAQ:ESPR) moving in opposite directions fo
Esperion Therapeutics stock slumps 22% premarket as data from study of cholestrol-lowering drug fail to impress investors
06:52am, Monday, 06'th Mar 2023
The stock of Esperion Therapeutics Inc. ESPR, -0.31% slumped 22% in premarket trade Monday, as investors seemed to question whether data from a major study of its cholesterol-lowering drug Nexletol sh
Esperion Therapeutics, Inc. (ESPR) Q4 2022 Earnings Call Transcript
02:10pm, Tuesday, 21'st Feb 2023
Esperion Therapeutics, Inc. (NASDAQ:ESPR ) Q4 2022 Earnings Conference Call February 21, 2023 8:00 AM ET Company Participants Tiffany Aldrich - Associate Director, Corporate Communications Sheldon Koe
Esperion Therapeutics (ESPR) Reports Q4 Loss, Misses Revenue Estimates
09:47am, Tuesday, 21'st Feb 2023
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 12.64% and 5.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock
Esperion to Report Fourth Quarter and Full Year 2022 Financial Results February 21, 2023
08:00am, Tuesday, 07'th Feb 2023
ANN ARBOR, Mich., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report fourth quarter and full year 2022 financial results before the open of the U.S. financial mar
Is Esperion Therapeutics (ESPR) Outperforming Other Medical Stocks This Year?
11:17am, Thursday, 08'th Dec 2022
Here is how Esperion Therapeutics (ESPR) and TransMedics (TMDX) have performed compared to their sector so far this year.
2 Biotech Stocks Options Traders Love Today
12:16pm, Wednesday, 07'th Dec 2022
At least two biotech stocks are triggering an options trading frenzy today, with Prometheus Biosciences Inc (NASDAQ:RXDX) and Esperion Therapeutics Inc (NASDAQ:ESPR) moving in opposite directions
Esperion Therapeutics: Q3 Earnings Reveal Progress Ahead Of CLEAR Outcomes Data
03:31am, Wednesday, 16'th Nov 2022
Esperion Therapeutics reported its Q3 earnings with a beat on EPS and a slight miss on revenue. The company was able to report significant revenue growth and encouraging commercial trends. The highly
Wall Street Analysts Think Esperion Therapeutics (ESPR) Could Surge 32%: Read This Before Placing a Bet
11:18am, Friday, 04'th Nov 2022
The consensus price target hints at a 32.5% upside potential for Esperion Therapeutics (ESPR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earn
Esperion (ESPR) Q3 Earnings Beat Estimates, Revenues Miss
02:18pm, Wednesday, 02'nd Nov 2022
Esperion Therapeutics (ESPR) reports mixed third-quarter results, beating earnings estimates but missing out on sales.
Esperion Therapeutics, Inc. (ESPR) Q3 2022 Earnings Call Transcript
02:03pm, Tuesday, 01'st Nov 2022
Esperion Therapeutics, Inc. (NASDAQ:ESPR ) Q3 2022 Earnings Conference Call November 1, 2022 8:00 AM ET Company Participants Tiffany Aldrich - Associate Director, Corporate Communications Sheldon Koen
Esperion Therapeutics (ESPR) Reports Q3 Loss, Misses Revenue Estimates
09:48am, Tuesday, 01'st Nov 2022
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 12.90% and 4.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stoc
Esperion to Report Third Quarter 2022 Financial Results November 1, 2022
08:02am, Monday, 17'th Oct 2022
ANN ARBOR, Mich., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2022 financial results before the open of the U.S. financial markets on Tuesday
